This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04698915
Recruitment Status : Terminated (Futility Analysis)
First Posted : January 7, 2021
Last Update Posted : December 13, 2023
Information provided by (Responsible Party):
Galera Therapeutics, Inc.

Brief Summary:
GTI-4711-201 is designed as a Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the effect to OS by adding GC4711 to SBRT following chemotherapy in patients with unresectable or borderline resectable nonmetastatic

Condition or disease Intervention/treatment Phase
SBRT Borderline Resectable Pancreatic Cancer Unresectable Pancreatic Cancer Drug: Drug GC4711 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 177 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: GRECO-2: A Randomized, Phase 2b Study of GC4711 in Combination With Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Unresectable or Borderline Resectable Nonmetastatic Pancreatic Cancer
Actual Study Start Date : May 7, 2021
Actual Primary Completion Date : November 30, 2023
Actual Study Completion Date : November 30, 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Arm A Active GC4711 Drug: Drug GC4711
15 Minute IV Infusion

Placebo Comparator: Arm B Placebo Drug: Placebo
15 Minute IV Infusion

Primary Outcome Measures :
  1. Median Overall Survival after SBRT completion [ Time Frame: From randomization up to 3 years ]

Secondary Outcome Measures :
  1. Median Progression Free Survival after SBRT Completion per RESIST 1.1 [ Time Frame: From randomization up to 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histological or biopsy proven adenocarcinoma of the pancreas. Cytology is acceptable if histology cannot be obtained.
  2. Newly diagnosed non-metastatic PC judged by tumor board to be feasible for SBRT
  3. Completed at least 6 weeks of chemotherapy consisting of FOLFIRINOX, mFOLFIRINOX, or a gemcitabine-based doublet regimen prior to start of SBRT
  4. Remain non-metastatic as confirmed by a CT scan at screening.
  5. Female or male subjects ≥ 18 years of age
  6. ECOG performance status of 0-2
  7. Adequate end-organ function

Exclusion Criteria:

  1. Subjects with documented metastatic disease
  2. First-line chemotherapy other than FOLFIRINOX, mFOLFIRINOX, and/or a gemcitabine-based doublet regimen
  3. Prior abdominal RT with substantial overlap in radiation fields
  4. Subjects not recovered/controlled from treatment-related toxicities
  5. Uncontrolled malignancy other than PC
  6. Uncontrolled gastric or duodenal ulcer disease within 30 days of dosing
  7. Visible invasion of bulky tumor into the lumen of the bowel or stomach on endoscopy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04698915

Show Show 35 study locations
Sponsors and Collaborators
Galera Therapeutics, Inc.
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Galera Therapeutics, Inc. Identifier: NCT04698915    
Other Study ID Numbers: GTI-4711-201
First Posted: January 7, 2021    Key Record Dates
Last Update Posted: December 13, 2023
Last Verified: December 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases